Owen Mumford Holdings Limited Reports FY2025 Financial Results: Key Highlights and Shareholder Insights
Key Financial Highlights for the Year Ended 30th September 2025
- Turnover: £68.6 million, driven predominantly by medical device and pharmaceutical services product sales.
- Profit Before Tax: £1.93 million.
- Profit for the Financial Year: £1.68 million.
- Total Comprehensive Income: £1.32 million, after accounting for exchange losses.
- Net Cash Position: Cash and cash equivalents at year-end stood at £29.65 million, up from £21.47 million at the previous year-end, reflecting a strong liquidity position.
- Shareholders’ Funds: Grew to £102.67 million, up from £101.8 million.
- Dividend Paid: £450,000 distributed to shareholders.
Operational Performance and Segment Analysis
- Geographical Breakdown:
- Europe & Scandinavia: £34.2 million
- Canada & USA: £24.0 million
- UK: £4.88 million
- Far East, South Asia, Australia/NZ, Africa, Middle East: remainder of sales
- Product Mix:
- Medical Devices (Product Sales): £42.5 million
- Pharmaceutical Services (Product Sales): £24.7 million
- Development, Services & Equipment: £1.4 million
- Profitability Drivers:
- Gross Profit: £33.1 million
- Operating Loss: £825,128, mainly due to high administrative expenses (£33.3 million)
- Profit on Sale of Fixed Assets: £2.12 million, providing a significant lift to the bottom line
- Interest Income: £670,164
Accounting and Audit Considerations
- Audit Qualification: The auditor issued a qualified opinion due to the absence of comparative financial information, as the statements were prepared solely to comply with Rule 3-05 of Regulation S-X for Embecta’s SEC reporting. This does not affect the fairness of presentation for the reported year but is a technical limitation investors should note.
- Accounting Standards: Financials were prepared under UK GAAP (FRS 102), with reconciliation to US GAAP provided. Key differences relate to lease accounting and investment property valuation, with a total US GAAP adjustment to income of -£46,420 and to equity of -£1.67 million.
Significant Events and Shareholder-Impacting Information
- Acquisition by Embecta: On 15 May 2026, Embecta Corporation acquired Owen Mumford Holdings Limited, making it a wholly-owned subsidiary. This is a major event and is likely to influence the Company’s future strategy, integration, and possibly the valuation of its shares. The financial statements were prepared, in part, to facilitate this transaction and Embecta’s regulatory reporting.
- Impairment Charges: The Company recognized a full impairment of intangible assets (£383,718), with a net book value of zero at year-end, and wrote off its unlisted investments (£815,820 carrying value impaired to nil). This indicates management’s conservative approach to asset valuation and possible future cost savings as these assets are no longer amortized.
- Capital Commitments: The Company has outstanding capital commitments of £6.2 million for plant and machinery as of year-end, indicating ongoing investment in production capacity and future growth.
- Pension Contributions: £2.03 million paid into defined contribution pension schemes, with £146k payable. There are no defined benefit obligations reported.
- Leverage and Security: The Company has a £4 million undrawn credit facility secured against UK freehold property. This provides ample headroom for liquidity but exposes part of the asset base to fixed charges.
- Operating Leases: Total future minimum lease payments under non-cancellable operating leases of £4.86 million, with £941k due within one year.
- Contingent Liabilities: An indemnity of £10,000 has been given to HMRC.
- Related Party Transactions: Minimal, with a single instance of rent foregone on a property occupied by a family member of a former founder, but not material to the accounts.
Risks, Uncertainties, and Management Judgements
- Standard Costing and Overhead Absorption: Inventory and gross margin calculations are based on standard costing derived from next year’s budget, which is a key area of estimation uncertainty for management and investors.
- Impairment of Intangible Assets: Development costs are subject to impairment testing, dependent on future product success and market demand – a risk area for future results.
- Going Concern: Directors have reviewed the Company’s ability to continue as a going concern and consider it appropriate, despite a challenging economic environment.
Taxation
- Effective Tax Rate: The effective tax rate was lower than the statutory 25% due to R&D credits, use of prior tax losses, and other reconciling items.
- Deferred Tax: Deferred tax liability of £4.1 million, mainly related to accelerated capital allowances and property revaluations, partially offset by tax losses carried forward.
Balance Sheet Strength
- Net Assets: £102.67 million, a solid equity base.
- Fixed Assets: £53.7 million, mostly in tangible assets such as property, plant, and equipment.
- Current Assets: £63.25 million, of which £29.6 million is cash, £17.8 million is inventory, and £15.8 million is receivables.
- Liabilities: Short-term creditors total £10.19 million, with no significant long-term debt reported.
Conclusion and Shareholder Implications
This set of results is highly significant for shareholders and potential investors for several reasons:
- The Embecta acquisition post-year-end is a major corporate event and may drive re-valuation, integration synergies, and strategic changes going forward.
- The Company remains in a strong financial position with robust cash reserves and limited leverage, supporting future growth and resilience.
- Impairment charges, conservative accounting, and a focus on core operating profitability provide a clearer, more prudent picture of company value.
- Ongoing investments in plant and machinery and a diversified geographical sales mix position the Company well for future expansion.
- Some risks remain around inventory costing, impairment judgements, and macroeconomic factors.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should consult their own professional advisers before making investment decisions. The views and data presented are based on the Owen Mumford Holdings Limited Consolidated Financial Statements for the year ended 30th September 2025 and subsequent events. Past performance is not indicative of future results.
